Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Smad Signaling Is Required to Maintain Epigenetic Silencing during Breast Cancer Progression

Open access
Papageorgis, Panagiotis, Lambert, Arthur W., Ozturk, Sait, Gao, Fangming, Pan, Hongjie, Manne, Upender, Alekseyev, Yuriy O., Thiagalingam, Arunthathi, Abdolmaleky, Hamid M., Lenburg, Marc, Thiagalingam, Sam·2010·Cancer Research

Abstract

Breast cancer progression is associated with aberrant DNA methylation and expression of genes that control the epithelial-mesenchymal transition (EMT), a critical step in malignant conversion. Although the genes affected have been studied, there is little understanding of how aberrant activation of the DNA methylation machinery itself occurs. Using a breast cancer cell–based model system, we found that cells that underwent EMT exhibited overactive transforming growth factor β (TGFβ) signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. Based on these observations, we hypothesized that activated TGFβ-Smad signaling provides an “epigenetic memory” to maintain silencing of critical genes. In support of this hypothesis, disrupting Smad signaling in mesenchymal breast cancer cells resulted in DNA demethylation and reexpression of the genes identified. This epigenetic reversal was accompanied by an acquisition of epithelial morphology and a suppression of invasive properties. Notably, disrupting TGFβ signaling decreased the DNA binding activity of DNA methyltransferase DNMT1, suggesting that failure to maintain methylation of newly synthesized DNA was the likely cause of DNA demethylation. Together, our findings reveal a hyperactive TGFβ-TGFβR-Smad2 signaling axis needed to maintain epigenetic silencing of critical EMT genes and breast cancer progression. Cancer Res; 70(3); 968–78

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-1872

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 177

Metadata

Authors
Papageorgis, P., Lambert, A. W., Ozturk, S., Gao, F., Pan, H., Manne, U., Alekseyev, Y. O., Thiagalingam, A., Abdolmaleky, H. M., Lenburg, M., & Thiagalingam, S.
Venue
Cancer Research
Published
2010-01-31
Volume
70
Issue
3
Pages
968-978
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2165899098
Cited by
177
References
1
FWCI
6.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Smad Signaling Is Required to Maintain Epigenetic Silencing during Breast Cancer Progression. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-1872
The paper
Papageorgis, P., Lambert, A. W., Ozturk, S., Gao, F., Pan, H., Manne, U., Alekseyev, Y. O., Thiagalingam, A., Abdolmaleky, H. M., Lenburg, M., & Thiagalingam, S. (2010). Smad Signaling Is Required to Maintain Epigenetic Silencing during Breast Cancer Progression. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-1872

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.